Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States

Manuela Di Fusco, Kinga Marczell, Kristen A. Deger, Mary M. Moran, Timothy L. Wiemken, Alejandro Cane, Solène de Boisvilliers, Jingyan Yang, Shailja Vaghela, Julie Roiz
doi: https://doi.org/10.1101/2022.02.24.22271478

Article usage

Article usage: February 2022 to March 2025

AbstractFullPdf
Feb 202219674117
Mar 202286429237
Apr 20223341544
May 202213791233
Jun 2022122261
Jul 202271412
Aug 202256818
Sep 202260212
Oct 202253219
Nov 20222937
Dec 20222114
Jan 202323312
Feb 20231646
Mar 20232537
Apr 202322513
May 202319211
Jun 2023765
Jul 20231315
Aug 202317125
Sep 2023133679
Oct 2023109126
Nov 202323139
Dec 20231424
Jan 20241254
Feb 20241317
Mar 20241203
Apr 2024634
May 202417111
Jun 20241439
Jul 2024709
Aug 202423812
Sep 20241317
Oct 2024916
Nov 202418314
Dec 20245315
Jan 20259213
Feb 202512358
Mar 202512334
Back to top
Posted February 25, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Public Health Impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States
Manuela Di Fusco, Kinga Marczell, Kristen A. Deger, Mary M. Moran, Timothy L. Wiemken, Alejandro Cane, Solène de Boisvilliers, Jingyan Yang, Shailja Vaghela, Julie Roiz
medRxiv 2022.02.24.22271478; doi: https://doi.org/10.1101/2022.02.24.22271478
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area